Advicenne S.A. (ALDVI.PA)
EUR 1.67
(0.12%)
EUR 1.67
(0.12%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.74 Million EUR | 77.29% |
| 2022 | 982 Thousand EUR | 36.96% |
| 2021 | 717 Thousand EUR | -2.45% |
| 2020 | 735 Thousand EUR | 48.16% |
| 2019 | 496.09 Thousand EUR | 21.47% |
| 2018 | 408.4 Thousand EUR | 65.85% |
| 2017 | 246.25 Thousand EUR | -15.38% |
| 2016 | 291 Thousand EUR | 66.29% |
| 2015 | 175 Thousand EUR | 821.05% |
| 2014 | 19 Thousand EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 1.72 Million EUR | -1.09% |
| 2024 Q2 | 1.72 Million EUR | 0.0% |
| 2023 Q1 | 1.66 Million EUR | 69.86% |
| 2023 FY | 1.74 Million EUR | 77.29% |
| 2023 Q4 | 1.74 Million EUR | 0.0% |
| 2023 Q3 | 1.74 Million EUR | 4.38% |
| 2023 Q2 | 1.66 Million EUR | 0.0% |
| 2022 FY | 982 Thousand EUR | 36.96% |
| 2022 Q4 | 982 Thousand EUR | 0.0% |
| 2022 Q3 | 982 Thousand EUR | 41.5% |
| 2022 Q2 | 694 Thousand EUR | 0.0% |
| 2022 Q1 | 694 Thousand EUR | -3.21% |
| 2021 Q3 | 717 Thousand EUR | 91.2% |
| 2021 Q1 | - EUR | -100.0% |
| 2021 FY | 717 Thousand EUR | -2.45% |
| 2021 Q4 | 717 Thousand EUR | 0.0% |
| 2021 Q2 | 375 Thousand EUR | 0.0% |
| 2020 FY | 735 Thousand EUR | 48.16% |
| 2020 Q4 | 735 Thousand EUR | 0.0% |
| 2020 Q1 | 543 Thousand EUR | 9.46% |
| 2020 Q2 | 543 Thousand EUR | 0.0% |
| 2020 Q3 | 735 Thousand EUR | 35.36% |
| 2019 FY | 496.09 Thousand EUR | 21.47% |
| 2019 Q2 | 473 Thousand EUR | 0.0% |
| 2019 Q1 | 473 Thousand EUR | 15.82% |
| 2019 Q4 | 496.09 Thousand EUR | 0.02% |
| 2019 Q3 | 496 Thousand EUR | 4.86% |
| 2018 Q4 | 408.4 Thousand EUR | 0.0% |
| 2018 FY | 408.4 Thousand EUR | 65.85% |
| 2018 Q3 | 408.4 Thousand EUR | 15.04% |
| 2018 Q2 | 355 Thousand EUR | 0.0% |
| 2018 Q1 | 355 Thousand EUR | 44.16% |
| 2017 Q2 | 270 Thousand EUR | 0.0% |
| 2017 Q3 | 163 Thousand EUR | -39.63% |
| 2017 Q4 | 246.25 Thousand EUR | 51.07% |
| 2017 FY | 246.25 Thousand EUR | -15.38% |
| 2017 Q1 | 270 Thousand EUR | -7.22% |
| 2016 Q3 | 291 Thousand EUR | 0.0% |
| 2016 Q1 | - EUR | 0.0% |
| 2016 Q4 | 291 Thousand EUR | 0.0% |
| 2016 FY | 291 Thousand EUR | 66.29% |
| 2015 FY | 175 Thousand EUR | 821.05% |
| 2014 FY | 19 Thousand EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| ABIONYX Pharma SA | 221 Thousand EUR | -687.783% |
| ABIVAX Société Anonyme | 1.00 EUR | -174099900.0% |
| Adocia SA | 272 Thousand EUR | -540.074% |
| Aelis Farma SA | 53 Thousand EUR | -3184.906% |
| Biophytis S.A. | - EUR | -Infinity% |
| genOway Société anonyme | 982.75 Thousand EUR | -77.156% |
| IntegraGen SA | 311.44 Thousand EUR | -459.0% |
| Medesis Pharma S.A. | 164.62 Thousand EUR | -957.574% |
| Neovacs S.A. | - EUR | -Infinity% |
| NFL Biosciences SA | -1.1 Million EUR | 257.037% |
| Plant Advanced Technologies SA | 1.22 Million EUR | -42.173% |
| Quantum Genomics Société Anonyme | -119.17 Thousand EUR | 1560.865% |
| Sensorion SA | - EUR | -Infinity% |
| Theranexus Société Anonyme | - EUR | -Infinity% |
| TME Pharma N.V. | 91 Thousand EUR | -1813.187% |
| Valbiotis SA | 1 Million EUR | -73.234% |
| TheraVet SA | 123.34 Thousand EUR | -1311.522% |
| Valerio Therapeutics Société anonyme | 1.00 EUR | -174099900.0% |
| argenx SE | 281.12 Million EUR | 99.381% |
| BioSenic S.A. | - EUR | -Infinity% |
| Celyad Oncology SA | 1.26 Million EUR | -38.175% |
| DBV Technologies S.A. | 1.00 USD | -174099900.0% |
| Galapagos NV | 73.97 Million EUR | 97.647% |
| Genfit S.A. | 4000.00 EUR | -43425.0% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 1.00 EUR | -174099900.0% |
| Innate Pharma S.A. | 1.00 EUR | -174099900.0% |
| Inventiva S.A. | 417 Thousand EUR | -317.506% |
| MaaT Pharma SA | 190 Thousand EUR | -816.316% |
| MedinCell S.A. | -6.71 Million EUR | 125.931% |
| Nanobiotix S.A. | 200 Thousand EUR | -770.5% |
| Onward Medical N.V. | 936 Thousand EUR | -86.004% |
| Oryzon Genomics S.A. | 6029.00 EUR | -28777.094% |
| OSE Immunotherapeutics SA | - EUR | -Infinity% |
| Oxurion NV | 128 Thousand EUR | -1260.156% |
| Pharming Group N.V. | 51.38 Million EUR | 96.612% |
| Poxel S.A. | 2.95 Million EUR | 41.103% |
| GenSight Biologics S.A. | 1.00 EUR | -174099900.0% |
| Transgene SA | - EUR | -Infinity% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 1.03 Billion EUR | 99.831% |
| Valneva SE | 44.46 Million EUR | 96.085% |
| Vivoryon Therapeutics N.V. | 1.00 EUR | -174099900.0% |